EP300 and urinary bladder carcinoma: Another study has suggested that some of the mutations of the histone acetyltransferase domain in EP300 and in the homologous acetyltransferase CREBBP encountered in bladder carcinoma patients would to reduction of their function and could be counteracted by treatment with histone de-acetylase inhibitor mocetinostat [44].